Sandoz Inc.
Sandoz Inc., a prominent global leader in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1886, Sandoz has established itself as a key player in generic pharmaceuticals and biosimilars, focusing on high-quality, affordable medications that enhance patient access to essential treatments. The company is renowned for its diverse portfolio, which includes a wide range of generic medicines, biosimilars, and over-the-counter products. Sandoz's commitment to innovation and quality sets it apart, as it continually invests in research and development to bring new therapies to market. With a strong market position, Sandoz has achieved notable milestones, including numerous successful product launches and a reputation for reliability in the healthcare sector.
DitchCarbon Score
How does Sandoz Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sandoz Inc.'s score of 68 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sandoz Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Sandoz Group AG, which may influence its climate commitments and reporting practices. While Sandoz Inc. has not outlined specific reduction targets or achievements, it is important to note that its climate initiatives and commitments are likely aligned with those of its parent company, Sandoz Group AG. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are cascaded from the parent organisation. As a part of the pharmaceutical industry, Sandoz Inc. is expected to adhere to industry standards for sustainability and climate action, although specific commitments or targets have not been disclosed at this time. The absence of detailed emissions data and reduction targets suggests that Sandoz Inc. may still be in the process of developing its climate strategy or reporting framework.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sandoz Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
